Get the Stockscreener App
25.23
3.19%
0.78
Pre-market:
25.11
-0.12
-0.48%
Zymeworks Inc. stock is traded at $25.23, with a volume of 753.75K.
It is up +3.19% in the last 24 hours and up +9.17% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$24.45
Open:
$24.96
24h Volume:
753.75K
Relative Volume:
1.03
Market Cap:
$1.90B
Revenue:
$122.87M
Net Income/Loss:
$-73.68M
P/E Ratio:
-25.74
EPS:
-0.9803
Net Cash Flow:
$-39.27M
1W Performance:
+4.60%
1M Performance:
+9.17%
6M Performance:
+79.19%
1Y Performance:
+97.88%
1-Day Range:
$24.59
$25.58
1-Week Range:
$22.26
$25.58
52-Week Range:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
25.23 | 1.84B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com India
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com UK
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet News
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - AOL.com
Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing - Nasdaq
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks
Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView
Zymeworks Inc. Q4 Loss Widens - Nasdaq
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative
$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan
Earnings Breakdown: Zymeworks Q4 - Sahm
Aug Levels: How sensitive is Zymeworks Inc to inflationMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
A Look Ahead: Zymeworks's Earnings Forecast - Benzinga
Zymeworks Inc. (ZYME) Stock Analysis: A High Upside Prospect with Promising Biotech Innovations - DirectorsTalk Interviews
Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews
Does Zymeworks Inc stock have upside surprise potential2025 Market Sentiment & Accurate Intraday Trade Tips - baoquankhu1.vn
Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares - Stock Titan
How Zymeworks Inc. (ZYME) Affects Rotational Strategy Timing - Stock Traders Daily
How Zymeworks Inc. stock valuations compare to rivalsTrade Exit Summary & Long-Term Capital Growth Ideas - mfd.ru
What is Zymeworks Inc.’s TAM (Total Addressable Market)Long Setup & Precise Buy Zone Identification - mfd.ru
Zymeworks Inc. (ZYME) Stock Analysis: A Biotech Gem With 57% Potential Upside - DirectorsTalk Interviews
Should I average down on Zymeworks Inc. stockJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Is Zymeworks Inc.’s ROE strong enough2025 Short Interest & Precise Trade Entry Recommendations - mfd.ru
Zymeworks Sets Date for 2025 Results and Corporate Update - TipRanks
Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):